Talk:GW Pharmaceuticals

This article is rated Stub-class on Wikipedia's content assessment scale.
It is of interest to the following WikiProjects:

Brands Low‑importance

	This article is within the scope of WikiProject Brands, a collaborative effort to improve the coverage of brands on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.BrandsWikipedia:WikiProject BrandsTemplate:WikiProject BrandsBrands articles
Low	This article has been rated as Low-importance on the project's importance scale.

Cannabis Mid‑importance

	Cannabis portal This article is within the scope of WikiProject Cannabis, a collaborative effort to improve the coverage of cannabis on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.CannabisWikipedia:WikiProject CannabisTemplate:WikiProject CannabisCannabis articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Companies Low‑importance

This article is within the scope of WikiProject Companies, a collaborative effort to improve the coverage of companies on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.CompaniesWikipedia:WikiProject CompaniesTemplate:WikiProject Companiescompany articles

Low This article has been rated as Low-importance on the project's importance scale.

WikiProject Companies To-do:

Here are some tasks awaiting attention:

Article requests : Wikipedia:Requested articles/Business and economics/Companies
Assess : Category:Unassessed company articles
Copyedit : Category:Company articles needing attention
Infobox : Category:Company articles needing infoboxes
Maintain : Portal:Companies
Stubs : Help expand stub articles located at Category:Company stubs
Other :
- Tag company articles with the {{portal|Companies}} template
- Tag company talk pages with the {{WikiProject Companies}} project banner
- Answer requests for comments

Guild of Copy Editors

This article was copy edited by Paulmnguyen, a member of the Guild of Copy Editors, on January 18, 2014.Guild of Copy EditorsWikipedia:WikiProject Guild of Copy EditorsTemplate:WikiProject Guild of Copy EditorsGuild of Copy Editors articles

Wiltshire Low‑importance

	This article is within the scope of WikiProject Wiltshire, a collaborative effort to improve the coverage of Wiltshire on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.WiltshireWikipedia:WikiProject WiltshireTemplate:WikiProject WiltshireWiltshire articles
Low	This article has been rated as Low-importance on the project's importance scale.

This article was created or improved during WikiProject Cannabis' "420 Collaboration" in 2020.

Tip: Anchors are case-sensitive in most browsers.

This article links to one or more target anchors that no longer exist.

[[Tetrahydrocannabinol#Dronabinol|Dronabinol]] Anchor Tetrahydrocannabinol#Dronabinol links to a specific web page: Dronabinol. The anchor (#Dronabinol) has been deleted by other users before.

Please help fix the broken anchors. You can remove this template after fixing the problems. | Reporting errors

Indiscriminate list of patents[edit]

Why do you think some of this patents indiscriminate ?? explain yourself before mass deleting. Vjiced (talk) 20:50, 5 November 2012 (UTC)[reply]

See WP:INDISCRIMINATE. Encyclopedia articles are not indiscriminate collections of information. We do not need to have a listing of every single patent that a company holds; if we did that for larger companies... well, this one is already absurdly long. --Aurochs (Talk | Block) 21:16, 5 November 2012 (UTC)[reply]

Also, in general, the fact that a company holds a patent is not in itself notable enough to include in an article. Lots of companies have patents. Further, the long list of patents makes the article significantly less readable. It's simply not a good thing to have for too many reasons. --Aurochs (Talk | Block) 21:26, 5 November 2012 (UTC)[reply]

Products in Development[edit]

Currently GW pharmacuticals are researching products for Cancer Pain ^[1]

References

^ pharmacuticals, G W. Products Pipline. GW pharmacuticals http://www.gwpharm.com/product-pipeline.aspx. Retrieved 18 November 2013. {{cite web}}: Missing or empty |title= (help)

Products in development redux[edit]

This needs to be toned down (saying that unapproved drugs "will be used to treat X" is promotional) and sourced to independent sources, as opposed to the company's website or conference abstracts (which are generally from the company for drugs in this stage of development) We also use generic names, not company brand names. We also look for secondary sources (conference abstracts are very primary sources)

Epidiolex

In 2015 GW Pharmaceutical was developing Epidiolex, an investigational cannabidiol liquid drug for epileptic children.^[1] It will be used to treat two orphan conditions, Dravet and Lennox-Gastaut syndromes.^[2] Phase 3 clinical trials for Epidiolex were conducted in 2015.^[3]^[4]^[5]

References

^ "GWPharma – Epidiolex". www.gwpharm.com. Retrieved 2016-02-03.
^ Butticè, Claudio (December 9, 2015). "Therapeutic Cannabis for children – a possible new treatment for epilepsy". Meds News. Retrieved February 3, 2016.
^ N. Jones, T. Hill, C. Stott, S. Wright. "Assessment of the Anticonvulsant Effects and Tolerability of GW Pharmaceuticals' Cannabidiol in the Anticonvulsant Screening Program". www.aesnet.org. American Epilepsy Society. Retrieved 2016-02-03.{{cite web}}: CS1 maint: multiple names: authors list (link)
^ Devinsky O.; et al. "Efficacy and Safety of Epidiolex (Cannabidiol) in Children and Young Adults with Treatment-Resistant Epilepsy: Update from the Expanded Access Program". www.aesnet.org. American Epilepsy Society. Retrieved 2016-02-03. {{cite web}}: Explicit use of et al. in: |last= (help)
^ Michael Oldham, Joseph Sullivan, Nilika Singhal, Nicole Tilton, Maria Cilio. "Long-term efficacy and tolerability of add-on cannabidiol for drug-resistant pediatric epilepsies". www.aesnet.org. American Epilepsy Society. Retrieved 2016-02-03.{{cite web}}: CS1 maint: multiple names: authors list (link)

-- Jytdog (talk) 03:41, 4 February 2016 (UTC)[reply]

Srich32977 thanks for toning down the PROMO but if you cannot find independent sources for this content please do not re-add it; and please don't re-add the primary sources from the company. We really hard to avoid that sort of thing in medical-related articles. I'd be happy to look but don't have time now. Thanks! Jytdog (talk) 04:00, 4 February 2016 (UTC)[reply]

i fixed it. Jytdog (talk) 04:10, 4 February 2016 (UTC)[reply]

– S. Rich (talk) 04:16, 4 February 2016 (UTC)[reply]

Claim of permission from Dutch government[edit]

The comment below was added to the article by an anonymous editor today.

Re: "grew and developed specialized strains of cannabis with permission from the Dutch government"

This claim is as false and fraudulent as it was when GW claimed Hortipharm had a licence from the dutch government. Hortipharm aka D Watson aka Sam the skunkman illegally produced seed for the home grown illegal cannabis market for the majority of the dutch cannabis seed companies and falsely claimed to have a licence for ten years between 1985 to 19 95 when the dutch government stated that NO LICENCE was ever grated to or held by Hortipharm NL or its directors. Permission would be a licence! Please supply verification of the licence number and the department who issued it, or the 'permission', because to date no verification has been supplied and no verification has been possible (or ever will be).

-- Wire723 (talk) 11:26, 15 November 2022 (UTC)[reply]

No comments received, so I removed the disputed sentence about Hortapharm. Wire723 (talk) 18:01, 30 November 2022 (UTC)[reply]

[1] rmacuticals, G W. Products Pipline. GW pharmacuticals http://www.gwpharm.com/product-pipeline.aspx. Retrieved 18 November 2013. {{cite web}}: Missing or empty |title= (help)

[2] "GWPharma – Epidiolex". www.gwpharm.com. Retrieved 2016-02-03.

[3] Butticè, Claudio (December 9, 2015). "Therapeutic Cannabis for children – a possible new treatment for epilepsy". Meds News. Retrieved February 3, 2016.

[4] N. Jones, T. Hill, C. Stott, S. Wright. "Assessment of the Anticonvulsant Effects and Tolerability of GW Pharmaceuticals' Cannabidiol in the Anticonvulsant Screening Program". www.aesnet.org. American Epilepsy Society. Retrieved 2016-02-03.{{cite web}}: CS1 maint: multiple names: authors list (link)

[5] Devinsky O.; et al. "Efficacy and Safety of Epidiolex (Cannabidiol) in Children and Young Adults with Treatment-Resistant Epilepsy: Update from the Expanded Access Program". www.aesnet.org. American Epilepsy Society. Retrieved 2016-02-03. {{cite web}}: Explicit use of et al. in: |last= (help)

[6] Michael Oldham, Joseph Sullivan, Nilika Singhal, Nicole Tilton, Maria Cilio. "Long-term efficacy and tolerability of add-on cannabidiol for drug-resistant pediatric epilepsies". www.aesnet.org. American Epilepsy Society. Retrieved 2016-02-03.{{cite web}}: CS1 maint: multiple names: authors list (link)

[1]

[1]

[2]

[3]

[4]

[5]